LDL-cholesterol reduction with PCSK9 inhibitors: A meta-analysis of randomised controlled trials

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease involved in lipid metabolism by mediating LDL receptor (LDLR) clearance through a post-transcriptional mechanism. The inhibition of PCSK9 results in increased expression of the hepatic LDL-R and in a consequent lipid-lowering effect. Since the role of PCSK9 in LDLR degradation and LDL-cholesterol (LDL-c) metabolism was discovered, different pharmacological approaches to inhibit this protein have been developed in a very short time.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - Category: Nutrition Authors: Source Type: research